1 / 7

Insulin Market Set to Expand by 2020-2027 with Profiling Players

An extensive study of the product application and services conducted by subject matter experts assessing the market will help product owners to make a wise decision.

priyapatil
Download Presentation

Insulin Market Set to Expand by 2020-2027 with Profiling Players

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Insulin Market To Reach USD 35.74 Billion By 2027

  2. Market Summary Increasing elderly populations, rising incidence of obese-related diabetes, and favorable reimbursement scenario are the key factors leading to the burgeoning growth in demand. Market Size – USD 24.47 Billion in 2018, Market Growth - CAGR of 4.2%, Market Trends – Growing incidence of diabetes.

  3. Our Approach Our Approach Market Summary The global Insulin Market is forecast to reach USD 35.74 Billion by 2027, according to a new report by Reports and Data. Insulin therapy is used for the treatment of patients with all types of diabetes. The need for insulin therapy depends upon the balance between insulin resistance and insulin secretion. Patients with type 1 diabetes require insulin treatment permanently unless they receive a whole organ pancreas transplant or an islet. Type 2 diabetes patients require insulin as their beta-cell function lowers over time. Diabetes and its complications, societal costs, and deaths have a huge and rapidly growing impact across the globe. In 2019: approximate 463 million adults (20-79 years) were living with diabetes and by 2045 this is expected to rise to 700 million. A growing number of diabetic patients are propelling the demand for insulin. The market in Asia Pacific is estimated to witness an increasing demand in the forecast period owing to growing awareness pertaining to medical treatments and care, rising health care sector, and an increase in R&D activities. Further, a rapid increase in the diabetic population and increasing adoption of insulin administration are driving the market demand in the region. Request for a sample of this research report @ https://www.reportsanddata.com/sample-enquiry-form/2338

  4. Our Approach Our Approach Market Summary Further key findings from the report suggest • The reason healthcare providers prescribe care users medications that can be injected with the help of an insulin pen is, the patient can inject the medicine himself/herself. The ability of care users to take medicine on their own and incorporate it in-home healthcare results in enhanced care user's adherence to care regimes that improve their quality of life and minimizes healthcare costs. • An insulin pump is a delivery device that pushes small, steady doses of rapid-acting insulin into a thin tube and is inserted underneath the patient's skin. There are several different kinds of insulin pumps available. These dosages are delivered repeatedly throughout the day. • Biosimilar insulins are a biological copy of an original insulin, and there is an increasing interest in developing and using them. These insulins are cheaper than original products, so they present the NHS with opportunities around availability and cost of care. However, there is a lack of awareness among healthcare professionals and people with diabetes about their use. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/insulin-market

  5. Our Approach Our Approach Market Summary Key participants include Novo Nordisk A/S, Sanofi, Eli Lily and Company, ADOCIA, Julphar, Pfizer, Inc., Oramed Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and GlaxoSmithKline Plc, among others. For the purpose of this report, Reports and Data have segmented into the global Insulin Market on the basis of product type, diseases, delivery devices, end-users, and region: Product Type Outlook (Revenue, USD Billion; 2016-2027) Basal or Long-Acting Insulin Bolus or Fast-Acting Insulin Traditional Human Insulin Combination Insulin Biosimilar Insulin Diseases Outlook (Revenue, USD Billion; 2016-2027) Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Prediabetes

  6. Our Approach Our Approach Market Summary End-Users Outlook (Revenue, USD Billion; 2016-2027) Home healthcare Hospitals Over the counter (OTC) Clinics Others Order Now: https://www.reportsanddata.com/checkout-form/2338

  7. Our Approach Our Approach About Us About Us Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

More Related